Loading current stock analysis…
Loading current stock analysis…
India
As of 18 Sept 2026, 03:30 pm
On September 17, 2026, AM Best assigned Niva Bupa Health Insurance Company Limited a Financial Strength Rating of A-, a Long-Term Issuer Credit Rating of 'a-', and an India National Scale Rating of aaa.IN, all with a stable outlook. These ratings reflect the company's very strong balance sheet strength and adequate operating performance over the fiscal years 2023-2026. The ratings also benefit from enhancements derived from its parent company, British United Provident Association Limited (Bupa Group). The company's capital adequacy ratio was at the strongest level as of March 31, 2026. While underwriting losses were offset by investment returns, the combined ratio improved to 102.0% in fiscal year 2026.
Yes, there have been recent changes. Effective September 16, 2026, Mr. Vikas Jain transitioned from Chief Investment Officer to Chief Transformation Officer, and Mr. Karan Bhatia was appointed as the new Chief Investment Officer. Additionally, on August 26, 2026, the company approved the allotment of 411,000 equity shares under its Employee Stock Option Plans, increasing its paid-up share capital and total number of shares.
As of September 18, 2026, the daily technical trend for Niva Bupa Health Insurance indicates a bearish SuperTrend direction with a value of 84.44, while the closing price was ₹79.59. The 200-day Simple Moving Average (SMA) was ₹79.43. In terms of recent performance, the stock has shown a return of 0.11 over the last six months and a year-to-date return of 0.06. However, it has experienced a current drawdown of -0.14 and a maximum drawdown of -0.26.
As of 18 Sept 2026, 03:30 pm
Recent drawdown and price variability remain within the producer's contained-risk thresholds.
Primary driver: Price swings are higher than typical
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
The session traded across a materially wider price range than usual.
Larger price swings can increase short-term uncertainty, especially if they continue.
The session opened materially below the previous close, indicating a sharp repricing at the open.
The price gap may increase short-term downside uncertainty and warrants review of the underlying context.
Latest complete financial results for Q4 FY2026 and comparative quarterly trends.
| Metric | Q4 FY2025-26(Latest) | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 | Q4 FY2024-25 |
|---|---|---|---|---|---|
| Gross Premiums Written | PEAK₹2,879.68 crore | ₹2,231.27 crore | ₹1,843.07 crore | ₹1,631.90 crore | ₹2,078.65 crore |
| Net Premium Written | PEAK₹2,301.66 crore | ₹1,766.70 crore | ₹1,450.06 crore | ₹1,287.87 crore | ₹1,672.11 crore |
| Net Retention Ratio | 0.7993 | 0.7918 | 0.7868 | 0.7892 | PEAK0.8044 |
| Expenses Of Management Ratio | 0.2849 | 0.331 | PEAK0.3889 | 0.3799 | 0.3633 |
| Incurred Claim Ratio | 0.5676 | 0.723 | 0.712 | PEAK0.7786 | 0.5641 |
| Combined Ratio | 0.8612 | 1.0819 | 1.1172 | PEAK1.1697 | 0.9278 |
The solvency ratio remained at 2.49 at the end of Q4, unchanged from the prior quarter but down from 3.03 a year ago. Despite the large quarterly profit, the ratio held steady—indicating that the profit‑driven increase in available capital was offset by growth in required capital, consistent with the rapid expansion in premiums.
Exchange disclosures and regulatory announcements for Niva Bupa Health Insurance Company.
Niva Bupa Health Insurance Company Limited has informed the Exchange about Credit Rating |SUBJECT: Credit Rating
On September 17, 2026, AM Best assigned Niva Bupa Health Insurance Company Limited a Financial Strength Rating of A-, a Long-Term Issuer Credit Rating of 'a-', and an India National Scale Rating of aaa.IN with a stable outlook. These ratings reflect the company's very strong balance sheet strength, adequate operating performance over the last four fiscal years (2023-2026), and rating enhancements derived from its parent company, British United Provident Association Limited (Bupa Group). The assessment highlights a Best's Capital Adequacy Ratio at the strongest level as of March 31, 2026, and notes that while underwriting losses were offset by investment returns, the combined ratio improved to 102.0% in fiscal year 2026.
Niva Bupa Health Insurance Company Limited has informed the Exchange regarding change in Management of the Company w.e.f September 16, 2026 |SUBJECT: Appointment
Niva Bupa Health Insurance announced effective immediately that Mr. Vikas Jain transitions from Chief Investment Officer to Chief Transformation Officer, and Mr. Karan Bhatia is appointed as the new Chief Investment Officer and Senior Management Personnel. Mr. Bhatia joined the company's investment team in December 2015 and has over 18 years of investment experience.
On August 26, 2026, Niva Bupa Health Insurance Company Limited's Stakeholders Relationship Committee approved the allotment of 411,000 equity shares to eligible grantees under the Employee Stock Option Plans of 2020 and 2024. This issuance increased the company's paid-up share capital from INR 18,492,337,030 to INR 18,496,447,030 and raised the total number of paid-up shares from 1,849,233,703 to 1,849,644,703. The Board had previously authorized the issuance on May 8, 2026, and no separate SEBI disclosure was required for this transaction.
On August 26, 2026, Niva Bupa Health Insurance Company allotted 4,11,000 equity shares of ₹10 each under its ESOP Schemes 2020 and 2024, with 1,92,100 shares from the 2020 plan and 2,18,900 from the 2024 plan. The allotment was approved by the Stakeholders Relationship Committee, and the shares rank pari-passu with existing shares. The paid-up equity share capital increased to ₹18,49,64,47,030, comprising 1,84,96,44,703 equity shares.
On August 19, 2026, the Insurance Regulatory and Development Authority of India (IRDAI) issued an order warning Niva Bupa Health Insurance Company Limited for non-compliance with Expense of Management limits during the financial year 2024-25. The regulator directed the company to refrain from opening new places of business for a six-month period starting from the date of the order. While the filing notes no quantifiable monetary impact, it confirms that the company remains compliant with EoM regulations for the fiscal years ending March 31, 2026, and June 30, 2026.
On August 19, 2026, the Insurance Regulatory and Development Authority of India (IRDAI) issued a warning to Niva Bupa Health Insurance Company Limited for non-compliance with Expense of Management (EoM) limits during the financial year 2024-25. The regulatory order prohibits the company from opening new places of business for a six-month period starting August 19, 2026, citing violations of Regulations 6, 10, 11, and 19 of the IRDAI (Expense of Management, including commission of insurers) Regulations, 2024. While the company asserts it is currently compliant for the fiscal years ending March 31, 2026, and June 30, 2026, the specific restriction remains in effect until February 18, 2027.
Recent market and company developments associated with Niva Bupa Health Insurance Company.
Breakout stocks to buy: Sumeet Bagadia recommends five breakout stocks to buy today — Colgate-Palmolive (India), Gmm Pfaudler, Niva Bupa Health Insurance Company, Capillary Technologies India, and Rossell Techsys.
Mumbai consumer forum passed the order in a case involving a ₹5 lakh health insurance claim for pancreatitis. The commission directed Max Bupa Health Insurance to pay the policyholder's claim after the insurer rejected it by citing a 24-month specific waiting period applicable to pancreatitis
Life insurers are seeking greater flexibility in expense caps, arguing that product-specific limits can constrain growing insurers as they invest in distribution, technology and expansion.
AI, gff, global fintech fest, insurance, trust gap, niva bupa deputy ceo, ankur kharbanda, whatsapp, insurance products
Eleven insurers have started transitioning to Ind AS in FY27, with IRDAI monitoring others for FY28 adoption.
A health insurer cannot automatically reject claims using waiting-period clauses. The Mumbai Consumer Commission ruled that insurers must prove a condition was pre-existing, not just rely on policy terms. This landmark decision emphasizes fairness and consumer protection, reminding policyholders to understand their policy's nuances and challenge unjustified rejections.
Top stocks in news: IndiGo, HAL, Amagi Labs, TMPV, Manipal Health, RailTel Corp, KIMS, Niva Bupa
Stock market today: On Thursday, the Nifty 50 ended the session 0.55% higher at 24,211, meanwhile, Sensex gained 0.75% to settle at 77,488.
Comprehensive Section Breakdown for Niva Bupa Health Insurance Company
Strategic Vision: Provides health insurance and services for Indian individuals.
Category: Financial Services
This segment primarily serves individual and family health insurance needs, constituting a significant portion of the company's business portfolio.
Category: Financial Services
Offers tailored insurance products and solutions for businesses and their employees.
• Knowledge and expertise in providing health services
• Comprehensive range of health insurance products
• Digital platform for service access and claims processing
Following three quarters of underwriting and net losses, Niva Bupa achieved a return to underwriting profitability in the fourth quarter of FY2025-26. The combined ratio dropped to 0.8612 from above 1 in each of the prior three quarters, reflecting sharp declines in both the incurred claim ratio and the expenses of management ratio. This improvement, together with strong premium growth and higher investment income, produced a profit after tax of ₹345.13 crore, the highest in the fiscal year and significantly above the prior‑year quarter.
Gross premiums written reached ₹2,879.68 crore in Q4, up 29.1% from the previous quarter and 38.5% from the same quarter a year ago. Net premiums written rose at a similar pace, increasing 30.3% sequentially and 37.7% year‑over‑year to ₹2,301.66 crore.
The net retention ratio—net premiums written as a share of gross premiums written—remained broadly stable at 0.7993. This was slightly below the 0.8044 recorded a year earlier but marginally above the 0.7918 in Q3. Across the five quarters shown, the company retained roughly 80% of gross premiums.
The incurred claim ratio fell to 0.5676 from 0.723 in Q3, a decline of 21.5%, and was nearly identical to the 0.5641 reported in the prior‑year quarter. The expenses of management ratio also decreased, dropping to 0.2849 from 0.331 in Q3 and from 0.3633 a year ago—sequential and year‑over‑year reductions of 13.9% and 21.6% respectively.
The combined ratio improved to 0.8612 from 1.0819 in Q3 and from 0.9278 in the year‑ago quarter. This marks the first quarter in the fiscal year where the combined ratio fell below 1, indicating that earned premiums covered claims and expenses.
After losses of ₹91.44 crore, ₹35.27 crore and ₹87.64 crore in the first three quarters, the company reported a profit after tax of ₹345.13 crore in Q4. That was 67.5% higher than the ₹206.08 crore profit in Q4 of the previous fiscal. Basic and diluted earnings per share rose to ₹1.87 from a loss of ₹0.47 in Q3 and from ₹1.13 a year earlier.
Net investment income increased 46.1% sequentially and 39.1% year‑over‑year to ₹130.47 crore, further boosting profits. Operating income grew 34.1% from the prior quarter to ₹2,077.66 crore, reflecting the expansion in premium earned and investment returns.
Niva Bupa’s fourth quarter reversed the pattern of underwriting losses seen in the first three quarters of FY2025‑26. A sharp reduction in both the incurred claim ratio and the expenses of management ratio brought the combined ratio below 1, restoring underwriting profitability. Together with strong premium growth and higher investment income, this delivered the highest quarterly profit in the fiscal year, substantially above the prior‑year quarter. The solvency ratio, while unchanged sequentially, declined over the fiscal year, as the boost to capital from profits was matched by an increase in required capital tied to premium growth.
Core Thesis: The company aims for aggressive market expansion through a digital-first approach and cost control to serve the Indian healthcare market.
• Digital-First Approach: Leveraging digital channels for distribution and service delivery, including a dedicated health app for convenient access and cashless claim processing. • Market Expansion: Focusing on aggressive growth strategies to reach a wider customer base across India. • Cost Control: Implementing measures to manage operational costs effectively while pursuing market expansion. • Product Innovation: Developing specialized products like 'Rise' to cater to underserved market segments such as the 'Missing Middle'.